Paraganglioma
Drug research and approvals for paraganglioma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 39 studies of paraganglioma are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 39
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 0
- Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal…NCT07920198 · Not reported · Azienda Ospedaliero-Universitaria di Modena · starts Jul 9, 2026
- Safety and Efficacy of Belzutifan in Preoperative Preparation for Patients With Pheochromocytoma/Paraganglioma (PPGL)NCT07907341 · Phase 4 · Longfei Liu,MD · starts Apr 1, 2026
- An Experimental Study of Belzutifan Impact on Catecholamine MetabolismNCT07680205 · Phase 2 · Cambridge University Hospitals NHS Foundation Trust · starts Apr 27, 2026
- Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and ParagangliomaNCT07288931 · Not applicable · Peking Union Medical College Hospital · starts Aug 6, 2024
- Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and ParagangliomaNCT07282587 · Phase 2 · Jazz Pharmaceuticals · starts Jan 2, 2026
- Cardiovascular Complications After Adrenalectomy for Pheochromocytoma and Non-secreting TumorsNCT07200245 · Not reported · Central Hospital, Nancy, France · starts Oct 1, 2025
- Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging…NCT07195500 · Not reported · Nanjing First Hospital, Nanjing Medical University · starts Dec 25, 2024
- Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL TrialNCT07167329 · Phase 2 · José Claudio Casali da Rocha · starts Jan 1, 2024
- An International Study on Pediatric Patients With Rare Tumors.NCT07072143 · Not reported · Azienda Ospedaliera di Padova · starts Jan 25, 2025
Approved 4
- IobenguanePheochromocytoma · Norepinephrine transporter substrate
- PhenoxybenzaminePheochromocytoma · Adrenergic receptor alpha antagonist
- MetyrosinePheochromocytoma · Tyrosine 3-hydroxylase inhibitor
- PhentolaminePheochromocytoma · Adrenergic receptor alpha antagonist
Phase 3 12 of 20
- TemozolomideDNA inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- CarboplatinDNA inhibitor
- DianhydrogalactitolDNA cross-linking agent
- FluciclovineDiagnostic agent
- LomustineDNA inhibitor
- CarmustineGlutathione reductase inhibitor
- Aminolevulinic acidDNA inhibitor
- Dordaviprone
- Ascorbic acidSupplement
- VorasidenibIDH1/IDH2 inhibitor
- FluorodopaDiagnostic agent
Phase 2 12 of 66
- Hiltonol
- EverolimusFK506-binding protein 1A inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- CyclophosphamideDNA inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- CapecitabineThymidylate synthase inhibitor
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- CelecoxibCyclooxygenase-2 inhibitor
- CisplatinDNA inhibitor
- SunitinibPheochromocytoma · Macrophage colony stimulating factor receptor inhibitor
- IvosidenibIsocitrate dehydrogenase [NADP] cytoplasmic inhibitor
- VinblastineTubulin inhibitor
Phase 1 or earlier 12 of 49
- TopotecanDNA topoisomerase I inhibitor
- RibociclibCyclin-dependent kinase 4 inhibitor
- GalunisertibTGF-beta receptor type I inhibitor
- EnzastaurinProtein kinase C beta inhibitor
- NiraparibPoly [ADP-ribose] polymerase 2 inhibitor
- IndoximodmTORC1 activator
- CytarabineDNA inhibitor
- Valproic acidSuccinate semialdehyde dehydrogenase inhibitor
- Fludarabine
- HydroxyureaRibonucleoside-diphosphate reductase RR1 inhibitor
- ImiquimodToll-like receptor 7 agonist
- PanobinostatHistone deacetylase inhibitor
How its trials ended
93 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 19 whose ending is known, 21% met their primary endpoint, 0% missed it and 79% stopped early.
- Ongoing4346%
- Completed, result not reported2224%
- Stopped: other or unclear1011%
- Status unknown910%
- Met its primary endpoint44%
- Stopped: enrollment or feasibility44%
- Stopped: sponsor or business decision11%
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Jul 30, 2018 | Azedra UltratraceAZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable,… | Progenics Pharmaceuticals, Inc. | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA